« Back
Home /
Dinaciclib

Dinaciclib

Item no.	CT-DINA-100
Manufacturer	ChemieTek
Amount	100mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	SCH 727965
Available
CASRN	779353-01-4
Synonym	SCH 727965
Brief Description	Dinaciclib (SCH 727965) is a potent and selective CDK inhibitor and a novel cytotoxic agent. It inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nM, respectively. It exhibits superior activity, compared with flavopiridol, with a much improved therapeutic index. It is currently in clinical trials.
Solubility	Soluble in DMSO
Storage	Store at 0° C (short term), -20° C (long term), desiccated
Purity	>99% chem and optical purity (HPLC and Chiral HPLC at 214 and 254 nm)
Original QC Data	HPLC-MS, ¹HNMR, Chiral HPLC, and Quantitative Elemental Analysis
Shipping Conditions	Ambient Temp.
References	1. D. Parry, et al, Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor, Mol Cancer Ther, 2010, 9(8); 2344-53 2. K. Paruch, et al, Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases, ACS Med. Chem. Lett., 2010, 1 (5), pp 204-208 3. G. Feldmann, et al, Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models, Cancer Biol. Ther. 2011, 12(7), 598-609

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100mg

available

Delivery expected until 9/6/2024